|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Imatinib-induced fatal acute liver failure显示文摘Imatinib mesylate is a drug that has been approved for treatment of chronic myeloid leukemia (CML) in blast crisis, accelerated or chronic phase, and also for advanced gastrointestinal stromal tumors. Severe hepatic toxicity and three deaths from hepatic failure have been reported. We report the case of a 51-year-old woman who was admitted to our institution with severe acute hepatitis. She was diagnosed with CML and began treatment with imatinib mesylate at a dose of 400 mg/d. Five months after beginning treatment, she developed severe hepatitis associated with coagulopathy, and was admitted to our institution. She had been consuming acetaminophen 500-1000 mg/d after the onset of symptoms. She had a progressive increase in bilirubin level and a marked decrease of clotting factor Ⅴ. Five days after admission, grade Ⅱ encephalopathy developed and she was referred for liver transplantation. Her clinical condition progressively deteriorated, and 48 h after being referred for transplantation she suffered a cardiac arrest and died. This report adds concern about the possibility of imatinib-mesylate-induced hepatotoxicity and liver failure, particularly in the case of concomitant use with acetaminophen. Liver function tests should be carefully monitored during treatment and, with the appearance of any elevation of liver function tests, treatment should be discontinued. | Ezequiel Ridruejo Roberto Cacchione Alejandra G Villamil Sebastián Marciano Adrián C Gadano Oscar G Mandó | 2007 | World Journal of Gastroenterology2007，13，48： | 5 |
| 2 | Fatty liver disease,an emerging etiology of hepatocellular carcinoma in Argentina显示文摘AIM To investigate any changing trends in the etiologies of hepatocellular carcinoma(HCC) in Argentina during the last years. METHODS A longitudinal cohort study was conducted by 14 regional hospitals starting in 2009 through 2016. All adult patients with newly diagnosed HCC either with pathology or imaging criteria were included. Patients were classified as presenting non-alcoholic fatty liver disease(NAFLD) either by histology or clinically, provided that all other etiologies of liver disease were ruled out, fatty liver was present on abdominal ultrasound and alcohol consumption was excluded. Complete follow-up was assessed in all included subjects since the date of HCC diagnosis until death or last medical visit.RESULTS A total of 708 consecutive adults with HCC were included. Six out of 14 hospitals were liver transplant centers(n = 484). The prevalence of diabetes mellitus was 27.7%. Overall, HCV was the main cause of liver disease related with HCC(37%) including cirrhotic and non-cirrhotic patients, followed by alcoholic liver disease 20.8%, NAFLD 11.4%, cryptogenic 9.6%, HBV 5.4% infection, cholestatic disease and autoimmune hepatitis 2.2%, and other causes 9.9%. A 6-fold increase in the percentage corresponding to NAFLDHCC was detected when the starting year, i.e., 2009 was compared to the last one, i.e., 2015(4.3% vs 25.6%; P < 0.0001). Accordingly, a higher prevalence of diabetes mellitus was present in NAFLD-HCC group 61.7% when compared to other than NAFLD-HCC 23.3%(P < 0.0001). Lower median AFP values at HCC diagnosis were observed between NAFLD-HCC and non-NAFLD groups(6.6 ng/m L vs 26 ng/m L; P = 0.02). Neither NAFLD nor other HCC etiologies were associated with higher mortality.CONCLUSION The growing incidence of NAFLD-HCC documented in the United States and Europe is also observed in Argentina, a confirmation with important Public Health implications. | Federico Pinero Josefina Pages Sebastián Marciano Nora Fernández Jorge Silva Margarita Anders Alina Zerega Ezequiel Ridruejo Beatriz Ameigeiras Claudia D’Amico Luis Gaite Carla Bermúdez Manuel Cobos Carlos Rosales Gustavo Romero Lucas McCormack Virginia Reggiardo Luis Colombato Adrián Gadano Marcelo Silva | 2018 | World Journal of Hepatology2018，10，1： | 4 |
| 3 | Early pancreatic cancer in Ig G4-related pancreatic mass:A case report显示文摘BACKGROUND IgG4-related disease can manifest diversely,including autoimmune pancreatitis and IgG4-related cholangiopathy.We are reporting a very unusual cause of pancreatic cancer triggered in a previously unknown IgG4-related disease.CASE SUMMARY A 75-year-old man was diagnosed with a 43 mm×33 mm pancreatic head tumor after consulting for abdominal pain and jaundice.A pancreaticoduodenectomy was carried out uneventfully,and the histopathology report showed an early stage of acinar-cell pancreatic cancer.The patient reconsulted on the 30th postoperative day with fever,jaundice and asthenia.Magnetic resonance cholangiopancreatography evidenced an extense bile duct stricture.A percutaneous biliary drainage proved to be ineffective,even after exchanging it with larger bore drainage.Reviewing the surgical specimen,features compatible with IgG4-related disease were observed.Consequently,empiric treatment with steroids was initiated achieving excellent results.CONCLUSION IgG4-related disease may cause chronic inflammation of the pancreas and can condition pancreatic malignancies. | Juan Glinka Francisco Calderón Martín de Santibanes Sung Ho Hyon Adrián Gadano Eduardo Mullen Melina Pol Juan Spina Eduardo de Santibanes | 2019 | World Journal of Gastrointestinal Surgery2019，11，12： | 3 |
| 4 | Intermediate-advanced hepatocellular carcinoma in Argentina:Treatment and survival analysis显示文摘BACKGROUND Hepatocellular carcinoma(HCC) represents the sixteenth most frequent cancer in Argentina. The rise of new therapeutic modalities in intermediate-advanced HCC opens up a new paradigm for the treatment of HCC.AIM To describe real-life treatments performed in patients with intermediateadvanced HCC before the approval of new systemic options.METHODS This longitudinal observational cohort study was conducted between 2009 and2016 in 14 different regional hospitals from Argentina. Included subjects had intermediate-advanced Barcelona Clinic Liver Cancer(BCLC) HCC stages(BCLC B to D). Primary end point analyzed was survival, which was assessed for each BCLC stage from the date of treatment until last patient follow-up or death.Kaplan Meier survival curves and Cox regression analysis were performed, with hazard ratios(HR) calculations and 95% confidence intervals(95%CI).RESULTS From 327 HCC patients, 41% were BCLC stage B, 20% stage C and 39% stage D.Corresponding median survival were 15 mo(IQR 5-26 mo), 5 mo(IQR 2-13 mo)and 3 mo(IQR 1-13 mo)(P < 0.0001), respectively. Among BCLC-B patients(n =135), 57% received TACE with a median number of 2 sessions(IQR 1-3 sessions).Survival was significantly better in BCLC-B patients treated with TACE HR =0.29(CI: 0.21-0.40) than those without TACE. After tumor reassessment by RECIST 1.1 criteria following the first TACE, patients with complete response achieved longer survival (HR = 0.15(CI: 0.04-0.56, P = 0.005))Eighty-two patients were treated with sorafenib, mostly BCLC-B and C(87.8%). However,12.2% were BCLC-D. Median survival with sorafenib was 4.5 mo(IQR 2.3-11.7 mo);which was lower among BCLC-D patients 3.2 mo(IQR 2.0-14.1 mo). A total of 36 BCLC-B patients presented tumor progression after TACE. In these patients,treatment with sorafenib presented better survival when compared to those patients who received sorafenib without prior TACE [HR = 0.26(CI: 0.09-0.71);P= 0.013].CONCLUSION In this real setting, our results were lower than expected. This highlights unmet needs in Argentina, prior to the introduction of new treatments for HCC. | Federico Pinero Sebastián Marciano Nora Fernández Jorge Silva Margarita Anders Alina Zerega Ezequiel Ridruejo Gustavo Romero Beatriz Ameigeiras Claudia D’Amico Luis Gaite Carla Bermúdez Virginia Reggiardo Luis Colombato Adrián Gadano Marcelo Silva | 2019 | World Journal of Gastroenterology2019，25，27： | 3 |
| 5 | Long-Term Treatment With Entecavir Induces Reversal of Advanced Fibrosis or Cirrhosis in Patients With Chronic Hepatitis B显示文摘 | Eugene R. Schiff Samuel S. Lee You–Chen Chao Seung Kew Yoon Fernando Bessone Shun–Sheng Wu Wieslaw Kryczka Yoav Lurie Adrian Gadano George Kitis Suzanne Beebe Dong Xu Hong Tang Uchenna Iloeje | 2011 | Clinical Gastroenterology and Hepatology2011，，3： | 3 |
| 6 | Efficacy of Entecavir With or Without Tenofovir Disoproxil Fumarate for Nucleos(t)ide-Na?ve Patients With Chronic Hepatitis B显示文摘 | Anna S. Lok Huy Trinh Giampiero Carosi Ulus S. Akarca Adrian Gadano Fran?ois Habersetzer William Sievert David Wong Meghan Lovegren David Cohen Cyril Llamoso | 2012 | Gastroenterology2012，，3： | 2 |
| 7 | Beneficial effects of the 2-days administration of terlipressin in patients with cirrhosis and hepatorenal syndrome显示文摘 | Hadengue A Gadano A Moreau R | 1998 | J Hepatol1998，29，： | 1 |
| 8 | Relapse rates in chronic hepatitis B na?ve patients after discontinuation of antiviral therapy with entecavir显示文摘 | E. Ridruejo S. Marciano O. Galdame M. V. Reggiardo A. E. Mu?oz R. Adrover D. Cocozzella N. Fernandez C. Estepo M. Mendizábal G. A. Romero D. Levi T. Schroder S. Paz H. Fainboim O. G. Mandó A. C. Gadano M. O. Silva | 2014 | J Viral Hepat2014，，8： | 1 |
| 9 | Hemodynamic and metabolic effects of terlipressin in patients with cirrhosis receiving a nonselectiveβ-blocker显示文摘 | Florence Vachiery MD Dr. Richard Moreau MD Dr. Adrian Gadano MD Song Yang MD Phillippe Sogni MD Antoine Hadengue MD Stephane Cailmail Thierry Soupison MD Didier Lebrec MD | 1996 | Digestive Diseases and Sciences1996，，9： | 1 |
| 10 | Beneficial effects of the two-day adminis-tration of terlipressin in patients with cirrhosis and hepatorenal syndrome 显示文摘 | Hadengue A Gadano A Moreau R | 1998 | J Hepatol1998，29，： | 1 |
| 11 | Terlipressin may influence the outcome of hepatorenal syndrome complicating alcoholic hepatitis显示文摘 | Cervoni JP Lecomte T Cellier C Auroux J Simon C Landi B Gadano A Barbier JP | | 0，，： | 1 |
| 12 | The role of nitric oxide in the hyperdynamic circulatory syndrome associated with portal hypertension显示文摘 | Ogni P Moreau R Gadano A | 1995 | J Hepatol1995，23，： | 1 |
| 13 | Aquaretic effects of niravoline,a kappa opioid agonist,in patients with cirrhosis显示文摘 | Gadano A Moreau R Pessione F | 2000 | J Hepatol2000，32，： | 1 |
| 14 | Beneficial effects of the 2-day administration of terlipressin in patients with cirrhosis and hepatorenal syndrome显示文摘 | Hadengue A Gadano A Moreau R Giostra E Durand F Valla D Erlinger S Lebrec D | | 0，，： | 1 |
| 15 | Transjugular intrahepatic portosystemic shunts: comparison with paracentesis in patients with cirrhosis and refractory ascites: a randomized trial显示文摘 | Didier Lebrec Nathalie Giuily Antoine Hadengue Valérie Vilgrain Richard Moreau Thierry Poynard Adrián Gadano Claudine Lassen Jean-Pierre Benhamou Serge Erlinger | 1996 | Journal of Hepatology1996，，2： | 1 |
| 16 | Natriuretic response to the combination of atrial natriuretic peptide and terlipressin in patients with cirrhosis and refractory ascites 显示文摘 | Gadano A | 1997 | Journal of hepatology1997，26，6： | 1 |
| 17 | Argentine folk medicine: genotoxic effects of Chenopodiaceae family 显示文摘 | Gadano AB Gurni AA Carballo MA | 2006 | J Ethnopharmacol2006，103，2： | 1 |
| 18 | Endoscopic Management of Biliary Complications After Adult Living-Donor Versus Deceased-Donor Liver Transplantation显示文摘 | Carlos Macías Gómez Jean-Marc Dumonceau Mariano Marcolongo Eduardo de Santiba?es Miguel Ciardullo Juan Pekolj Martín Palavecino Adrian Gadano Jorge Dávolos | 2009 | Transplantation2009，，11： | 1 |
| 19 | Triple therapy with daclatasvir (DCV; BMS-790052), peginterferon alfa/2a and ribaviron in HCV-infected prior null and partial responders: 12 week results of phase 2b command-2 trial显示文摘 | Katziu V Gadano A Pol S | 2012 | J Hepatol2012，6，2： | 1 |
| 20 | Beneficial effects of the 2- day administration of terlipressin in patients with cirrhosis and hepatorenal syndrome 显示文摘 | Hadengue A Gadano A Moreau R | 1998 | J Hepatol1998，29，4： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员